Wave Life Sciences Ltd. (WVE) Stock: Navigating the Market Volatility

The stock of Wave Life Sciences Ltd. (WVE) has seen a 4.95% increase in the past week, with a 17.16% gain in the past month, and a 11.24% flourish in the past quarter. The volatility ratio for the week is 5.91%, and the volatility levels for the past 30 days are at 8.85% for WVE. The simple moving average for the last 20 days is -3.93% for WVE stock, with a simple moving average of 20.66% for the last 200 days.

Is It Worth Investing in Wave Life Sciences Ltd. (NASDAQ: WVE) Right Now?

Company’s 36-month beta value is -1.08.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for WVE is 95.63M, and currently, short sellers hold a 3.13% ratio of that floaft. The average trading volume of WVE on April 04, 2024 was 921.26K shares.

WVE) stock’s latest price update

The stock of Wave Life Sciences Ltd. (NASDAQ: WVE) has decreased by -4.96 when compared to last closing price of 6.25. Despite this, the company has experienced a 4.95% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-03-27 that CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in April.

Analysts’ Opinion of WVE

Many brokerage firms have already submitted their reports for WVE stocks, with Leerink Partners repeating the rating for WVE by listing it as a “Outperform.” The predicted price for WVE in the upcoming period, according to Leerink Partners is $12 based on the research report published on December 19, 2023 of the previous year 2023.

Raymond James, on the other hand, stated in their research note that they expect to see WVE reach a price target of $7. The rating they have provided for WVE stocks is “Outperform” according to the report published on July 05th, 2023.

Jefferies gave a rating of “Hold” to WVE, setting the target price at $5 in the report published on May 24th of the previous year.

WVE Trading at 17.64% from the 50-Day Moving Average

After a stumble in the market that brought WVE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.56% of loss for the given period.

Volatility was left at 8.85%, however, over the last 30 days, the volatility rate increased by 5.91%, as shares surge +24.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.65% upper at present.

During the last 5 trading sessions, WVE rose by +4.95%, which changed the moving average for the period of 200-days by +51.92% in comparison to the 20-day moving average, which settled at $6.24. In addition, Wave Life Sciences Ltd. saw 17.62% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at WVE starting from RA CAPITAL MANAGEMENT, L.P., who purchase 1,000,000 shares at the price of $5.00 back on Dec 11 ’23. After this action, RA CAPITAL MANAGEMENT, L.P. now owns 19,202,009 shares of Wave Life Sciences Ltd., valued at $5,000,000 using the latest closing price.

GSK plc, the 10% Owner of Wave Life Sciences Ltd., purchase 3,300,000 shares at $5.00 during a trade that took place back on Dec 07 ’23, which means that GSK plc is holding 13,983,761 shares at $16,500,000 based on the most recent closing price.

Stock Fundamentals for WVE

Current profitability levels for the company are sitting at:

  • -0.6 for the present operating margin
  • 0.92 for the gross margin

The net margin for Wave Life Sciences Ltd. stands at -0.48. The total capital return value is set at -0.77. Equity return is now at value -1123.17, with -27.42 for asset returns.

Based on Wave Life Sciences Ltd. (WVE), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at -0.6. The debt to equity ratio resting at 0.68. The interest coverage ratio of the stock is 23.61.

Currently, EBITDA for the company is -58.79 million with net debt to EBITDA at 2.49. When we switch over and look at the enterprise to sales, we see a ratio of 4.93. The receivables turnover for the company is 5.37for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.26.


In a nutshell, Wave Life Sciences Ltd. (WVE) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts